Logo

American Heart Association

  55
  0


Final ID:

Discussant: MUSIC-HFpEF

  • Kawana, Masataka  ( STANFORD UNIVERSITY , Stanford , California , United States )
  • Author Disclosures:
    Masataka Kawana: DO have relevant financial relationships ; Consultant:Edwards Lifesciences:Active (exists now) ; Research Funding (PI or named investigator):FANCL Corp.:Active (exists now) ; Advisor:Holosis Health:Active (exists now) ; Advisor:Cardiac RSK3 Inhibitors, LLC:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Biological and Pragmatic Interventions in Heart Failure: From Present to Future

Sunday, 11/09/2025 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure - BioVAT-HF-DZHK20 – Phase II Interim Data Report

Ensminger Stephan, Fujita Buntaro, Gerecke Birgit, Hasenfuss Gerd, Hellenkamp Kristian, Herrmann-lingen Christoph, Jebran Ahmad-fawad, Jurczyk Dominik, Kowallick Johannes, Legler Tobias, Lotz Joachim, Kutschka Ingo, Placzek Marius, Puehler Thomas, Riggert Joachim, Sadlonova Monika, Tiburcy Malte, Zimmermann Wolfram, Paitazoglou Christina, Seidler Tim, Brandenburg Soeren, Anker Stefan, Bremmer Felix, Eitel Ingo, Friede Tim

First-in-Human Gene Therapy Trial for Patients with Heart Failure with preserved Ejection Fraction (HFpEF)

Fudim Marat, Rudy Jeffrey, Guerrero Janet, Chan Camie, Patel Manesh, Bavry Anthony, Li Ronald, Sarma Satyam, Macnamara James, Levine Benjamin, Hajjar Roger, Ascheim Deborah, Grodin Justin, Kittipibul Veraprapas, Doukellis Katheryn, Dhimitri Andy, Fitzhugh Robert, Karmat Niharika, Costa Kevin

More abstracts from these authors:
Precision therapy for Genetic HCM: Cardiac Myosin Inhibitors

Kawana Masataka, Wilsbacher Lisa, Wheeler Matthew

You have to be authorized to contact abstract author. Please, Login
Not Available